Special Issue "ROS Derived from NADPH Oxidase (NOX) in Angiogenesis"
A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section "Health Outcomes of Antioxidants and Oxidative Stress".
Deadline for manuscript submissions: closed (31 March 2017).
Interests: reactive oxygen species; NADPH oxidase; angiogenesis; redox signaling; endothelial cell; ischemic disease; wound healing; cancer; atherosclerosis; vascular biology
Special Issues and Collections in MDPI journals
Angiogenesis, a process of new blood vessel growth, contributes to normal development, wound healing and treatment of ischemic heart and limb diseases, as well as various pathophysiologies such as cancer, diabetic retinopathy and atherosclerosis. Reactive oxygen species (ROS), such as O2− and H2O2 at excess levels are detrimental and toxic, while , at physiological concentrations, they can act as second messengers to regulate reparative and pathological angiogenesis and vascular repair. Accumulating evidence suggests that ROS derived from NADPH oxidase (NOX), especially NOX4 and NOX2, play an important role in angiogenic signaling via activating redox-sensitive kinases and inactivating protein tyrosine phosphatase via oxidative inactivation of reactive cysteine residues. Furthermore, they are involved in regulating redox-sensitive angiogenic genes, such as HIF1alpha and VEGF in endothelial cells (ECs). The purpose of this Special Issue is to highlight recent progress on the emerging area of the role of ROS derived from NOX4 and NOX2 in angiogenic signaling in ECs, as well as physiological and pathological angiogenesis in vivo and their underlying mechanisms. Suppressing pathological neovascularization in the retina and tumors and enhancing therapeutic angiogenesis—such as wound healing and ischemia- or exercise-induced revascularization by manipulating NOXs, their regulators and ROS targets—appears to be an attractive therapeutic strategy to treat diabetic retinopathy, cancer and ischemic heart and peripheral vascular diseases.
Prof. Dr. Masuko Ushio-Fukai
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Reactive oxygen species
- NADPH oxidase
- Redox signaling
- Endothelial cell
- Ischemic disease
- Wound healing
- Diabetic retinopathy